Lucid Diagnostics Inc. (LUCD)
- Previous Close
0.6831 - Open
0.6800 - Bid 0.6360 x 100
- Ask 0.7141 x 100
- Day's Range
0.6306 - 0.6800 - 52 Week Range
0.6300 - 1.8500 - Volume
235,209 - Avg. Volume
173,967 - Market Cap (intraday)
32.329M - Beta (5Y Monthly) 1.62
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2600 - Earnings Date Mar 26, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.83
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
www.luciddx.comRecent News: LUCD
Performance Overview: LUCD
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LUCD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LUCD
Valuation Measures
Market Cap
32.33M
Enterprise Value
47.31M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.52
Price/Book (mrq)
--
Enterprise Value/Revenue
19.49
Enterprise Value/EBITDA
-0.95
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-101.38%
Return on Equity (ttm)
-507.97%
Revenue (ttm)
2.43M
Net Income Avi to Common (ttm)
-52.67M
Diluted EPS (ttm)
-1.2600
Balance Sheet and Cash Flow
Total Cash (mrq)
20.88M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-15.24M